At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
Single dose of SUF NT 15 mcg +1 moredrug
Likely dose
Single dose of SUF NT 15 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single- and Multiple-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab® PCA System (Zalviso™) in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Single dose of SUF NT 15 mcg and 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes for Plasma Concentrations. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlasma Concentrations
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionFeb 2013
TodayJul 2026
First PostedJan 7, 2013
Enrollment StartJan 1, 2013
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.5 years ago
Interventions
Single dose of SUF NT 15 mcgdrug
40 consecutive doses of SUF NT 15 mcg taken every 20 minutesdrug